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Abstract
Intravenous immunoglobulin (IVIG) has shown limited promise so far in human clinical studies 
on Alzheimer’s disease (AD), yet overwhelmingly positive preclinical work in animals and human 
brain cultures support the notion that the therapy remains potentially efficacious. Here, we 
elaborate on IVIG neuropreservation by demonstrating that IVIG protects human primary neurons 
against oxidative stress in vitro and that IVIG preserves antioxidant defense mechanism in vivo. 
Based on these results, we propose the following translational impact: If the dosage and treatment 
conditions are adequately optimized, then IVIG treatment could play a significant role in 
preventing and/or delaying the progression of neurodegenerative diseases, such as AD. We 
suggest that IVIG warrants further investigation to fully exploit its potential as an anti-oxidant, 
neuroprotective and synapto-protecting agent.
Introduction
Alzheimer’s disease (AD) is an age-dependent neurodegenerative disorder with no curative 
treatment options. According to the latest data, nearly 44 million people worldwide are 
suffering from AD [1]. Despite the vast amount of research in the neurochemistry and 
pharmacology of AD, there is no effective treatment available to modify the underlying 
pathology of this devastating disease; therefore, vigorous research at various fronts is needed 
[2–3]. Since AD is a multifactorial disease with genetic and environmental etiologies, 
including lifestyle, diet, stress and toxic exposures [4–5], there is no consensus of the causes 
of selective neuronal vulnerability in AD. Neurochemical dysfunctions associated with AD 
include the accumulation of inflammatory factors and reactive oxygen species (ROS), 
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particularly within the hippocampal complex that mediates memory function [6–7]. These 
factors contribute to pathological cascades leading to neurodegeneration and synaptic loss 
and AD.
There are five FDA drugs currently approved for use in AD patients. However, they provide 
only slight symptomatic improvements and do not appear to modify disease progression. 
Therefore, a central focus of AD research is to test and develop agents that should prevent 
selective neuronal vulnerability and eventually the onset of symptomatic disease. Our 
laboratory is testing novel functions of important therapeutic agents in animal and cell 
culture models [8–10] as well as important strategies such as phytochemicals [11] and 
immunotherapy [12].
The most prevalent hypothesis is that AD results from the accumulation of potentially toxic 
amyloid-β (Aβ) peptides as extracellular senile plaques [7]. Aβ is cleaved from the amyloid-
β precursor protein (APP) sequentially by β-secretase (or BACE1) and γ–secretase activity. 
Unfortunately, immunotherapeutic strategies targeting Aβ peptides have been unable to 
improve cognition in people with mild AD [13–14]. In addition, these clinical trials caused 
severe side effects [15]. For these reasons, other alternative targets and treatment options are 
being tested. It is reasoned that intravenous immunoglobulin (IVIG) therapy might be a 
novel alternative immunotherapy with significant advantages over amyloid-based strategies 
[16–17]. In a recent multicenter, placebo-controlled, double-blinded phase III trial of 390 
subjects, the Gammaglobulin Alzheimer’s Partnership (GAP) study did not meet primary 
endpoints of slowing cognitive and functional decline after 18 months of treatment of 
Gammagard [18]. However, two useful positive results emerged from the GAP study results: 
IVIG’s positive safety profile and IVIG’s beneficial effects for pre-specified moderate AD 
and apoEε4 carrier subgroups [18].
Based on these results from the GAP trial, several studies are exploring the phenomenon of 
IVIG neuroprotection in tissue culture and animal models of AD pathology. Some animal 
studies have shown encouraging results in a variety of biochemical and behavioral 
parameters [19–21]. IVIG treatment protects mouse neurons from Aβ toxicity and, 
importantly, IVIG passes via the blood-brain barrier and binds to Aβ deposits in brain 
parenchyma [19]. Using the neuronal cell culture and transgenic (Tg) mouse models of AD, 
IVIG treatment has been shown to reduce hallmark AD pathology, including amyloid 
plaques, neurofibrillary tangles, inflammation, glial activation and oxidative stress [21–24]. 
IVIG administration has also shown beneficial effects on inflammation and synaptic 
function AD transgenic mice [21,22]. At the tissue culture front, initial experiments suggest 
that IVIG-treatment increased levels of synaptic proteins in primary rat hippocampal 
neurons versus vehicle-treated cells [23–24]. Furthermore, when the neuronal cells were 
challenged with oxidative stress agents, the IVIG treatment protected against neurotoxic 
insults. Therefore, IVIG treatment displays significant translational value for unveiling AD 
pathogenic mechanisms and potential preventive and therapeutic strategies for AD.
To characterize the role of IVIG in preclinical models, we have performed a series of studies 
on the effects of IVIG (Gammagard, 10%, Baxter Healthcare) in both primary human fetal 
brain (HFB) cultures [25] and in the 3xTg mouse model of AD [21]. Here we report that 
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IVIG preserves HFB viability and protects these cultures from oxidative stress. Moreover, 
studies in the 3xTg mouse reveal that IVIG preserves the expression levels of key anti-
oxidants in the face of mounting AD-like pathology. These results suggest that IVIG plays a 
neuropreservative role by reducing the toxic effects of ROS and support a growing list of 
potential pro-survival properties of this well-tolerated immunotherapy.
Experimental model and design
Primary Human Fetal Brain Cultures and Treatment Conditions
The HFB cultures were prepared [26] and treated at DIV16 with different doses (5–20 
mg/ml) of IVIG (Gammagard, 10%; Baxter Healthcare) (n=4) for 72 hr, as indicated in the 
figures. The HFB cultures were also separately treated with glycine and Buminate (Baxter 
Healthcare) to serve as vehicle and placebo, respectively. For the ROS experiments, the cell 
culture contained ‘antioxidant-free B27’ media for each respective treatment. Following 
IVIG treatments, media was aspirated off from the plate, and the HFB cells were washed 
with PBS. The HFB cells were then treated with fresh media containing either IVIG alone or 
50μM H2O2 (representing ROS) without the addition of IVIG. The HFB cells were 
harvested after 24 hr of H2O2 exposure, and morphology was recorded by imaging and 
immunocytochemistry (ICC). Effects of IVIG alone on neurons were assessed for the 
cellular viability assay by Cell Titer Glo (CTG) and for toxicity by the lactate 
dehydrogenase (LDH) assay; details of these procedures have been previously described 
[26].
3xTg Mouse Treatments and Analysis
3xTg mice, a well-established mouse model for AD bearing human mutant APPswe, 
PS1M146V, and TauP301L transgenes, were randomized into experimental and placebo 
groups at three months of age and treated for either three or six months [21]. The 
experimental groups (n = 15) received 400 mg/kg bodyweight of Gammagard, 10% (Baxter 
Healthcare) intravenously via the retro-orbital sinus every two weeks under anesthesia. This 
dosage was consistent with dosage levels tested in the GAP trial. The placebo group 
received injections of 10% heat-inactivated bovine serum albumin (Sigma) in saline. A 
baseline cohort (three months old, no treatment, n = 8) was also evaluated. Mice were 
transcardially perfused with saline and brains from each group were hemisected. One 
hemisphere was immersion-fixed in 4% paraformaldehyde/0.1% glutaraldehyde for 24 hr 
and stored in cryoprotectant. From the other hemisphere, hippocampus, frontoparietal 
cortex, and cerebellum were rapidly dissected and snap-frozen [12–14].
Plasma collection
Cardiac puncture of the right ventricle was performed to draw ~300 μl blood prior to 
perfusion of each animal. Animals were fasted overnight prior to sacrifice to control for 
metabolic fluctuations. Blood was drawn into EDTA-treated tubes and immediately spun at 
1500 rpm for 10 min at 4 °C to separate the plasma, buffy coat, and erythrocyte fractions. 
Plasma was snap-frozen and stored at −80 °C.
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Plasma mRNA amplification and custom microarray analysis
mRNA from collected plasma fractions was extracted in Trizol (Life Tech) and amplified 
using terminal continuation RNA amplification methodology, as previously reported [21]. A 
detailed description of this method can be found at http://cdr.rfmh.org/Labgoups/
ginsberg_protocol.html. The last step of the process uses neuronal cDNA as a template to 
synthesize radiolabeled hybridization probes by in vitro transcription. Probes are then 
hybridized to custom-designed microarrays with 576 cDNAs encoding functional gene 
classes mediating critical cellular pathways [27,28]. Each array was analyzed on a Storm 
phosphor imager with ImageQuant software (GE, Piscataway, NJ). RNA bound to each 
cDNA was expressed as a ratio of the total hybridization signal intensity of the array (i.e., 
global normalization) [27,28], thereby minimizing variations due to differences in the 
specific activity of the probe and the absolute quantity of probe present [27,28]. Data 
analysis generated expression profiles of the relative changes in mRNA levels for 
quantitative comparison among baseline, IVIG- and placebo-treated animals.
Quantitative PCR (qPCR)
qPCR was performed on frozen hippocampal tissue from placebo and IVIG-treated mice (n 
= 6). Samples were assayed on a real-time PCR cycler (7900HT, Applied Biosystems) in 96-
well optical plates as described previously [27,28]. The ddCT method was employed to 
determine relative SYP, APP, SYN1, and SYT1 gene level differences with glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) qPCR products used as a control [27,28].
Statistical analysis
Array and qPCR-based expression levels among the baseline, placebo, and IVIG groups 
were compared using one-way ANOVA with Bonferroni’s post hoc test for multiple 
comparisons. Expression levels on the custom arrays were analyzed using GeneLinker 
bioinformatics software (IOS, Kingston, ON). P-values were adjusted using a false 
discovery rate controlling procedure to reduce type I error due to the large number of genes 
analyzed simultaneously. The level of significance was set at α = 0.01 (two-tailed).
Results
1. Effect of IVIG on Cellular Toxicity by LDH Assay
An LDH based assay of cell integrity was performed on conditioned medium samples and 
lysates of the adherent cells. Increased LDH release is directly proportional to increased 
membrane damage and cell lysis. The data are shown as the percentages of total LDH in the 
conditioned medium of the cells from each treatment vs. the control set to 100% (Fig. 1). 
There was a significant decrease in LDH release with IVIG treatmnt vs the control media 
(Fig. 1) (p < 0.05). This suggests that the integrity of the cell membrane is preserved and 
enhanced with IVIG relative to control treatment.
2. Effect of IVIG Treatments on Neuronal Viability in HFB Neuronal Cultures
Neuronal viability was assayed by the sensitive CTG measurements. CTG assay showed a 
significant increase in cell viability with high dose of IVIG (20 mg/mL) treatment (p < 
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0.05). CTG results suggest that the range of IVIG doses tested was well-tolerated by the 
primary neuron-enriched human fetal brain cultures (at DIV16) (Fig. 2). Cellular 
morphology did not show any change at any concentration of IVIG tested (data not shown). 
Thus, IVIG treatments were well tolerated and able to promote neurite extension.
3. Effect of IVIG Treatments on Neuropreservation and Neuroprotection
When human primary neuronal cultures were treated with different doses of IVIG, and 
concurrently challenged with oxidative stress-promoting agents (50 μM of ROS), we noted a 
significant neuropreservation with IVIG (10 to 20 mg/mL) from the placebo (data not 
shown). These results suggest that IVIG treatment is neuropreservative in human neurons. In 
another set of experiments, when human primary neurons were treated with different doses 
of IVIG, and cells were washed off excessive IVIG, and then subsequently challenged with 
50 μM of ROS alone for 24 hr, cellular morphology revealed significant neuroprotection 
with IVIG relative to placebo (data not shown). Here, HFB cells were first exposed with 
H2O2 for 24 hr, and then cells were washed with PBS. The HFB cells were further treated 
with either medium, glycine, Buminate, IVIG 10 mg/ml or IVIG 20 mg/ml for 72 hr. At the 
end of the treatments, the CTG-based cell viability assay was performed with an equal 
volume of cell suspension. The CTG assay showed a significant decrease in cell viability 
when the cells were pretreated with ROS (vehicle + ROS). Brain cultures containing 
neurons were not rescued against ROS pre-exposure in the presence of either glycine or 
Buminate (Fig. 3). Notably, neuron containing cultures were gradually rescued against ROS 
pre-exposure in the presence of increasing dose of IVIG (Fig. 3). Thus, IVIG pre-treatment 
protects human neurons from ROS-mediated damage.
4. IVIG preserves key antioxidant levels in the 3xTg mouse model of AD
To understand potential mechanisms for IVIG-mediated neuroprotection and preservation of 
primary neuronal cultures against ROS, we looked to plasma gene expression profiling 
experiments that were performed on 3xTg mice treated with intravenous IVIG or placebo for 
six months. When compared to placebo, IVIG preserved plasma levels of several key 
antioxidant enzymes, including superoxide dismutase 2 (SOD2), catalase (CAT), glutathione 
S-transferase (GST1), and glutathione peroxidase (GPX1) (Fig. 4A). Notably, preservation 
of SOD2 and GST1 gene expression was also observed in hippocampal tissue from the same 
IVIG-treated mice relative to placebo (Fig. 4B), indicating that IVIG modifies AD-like 
disease progression in preclinical models by stimulating a strong antioxidant response. 
Moreover, these data suggest that antioxidant mRNA levels in plasma may be reliable 
prognostic biomarkers for IVIG therapeutic efficacy.
Discussion
We have previously reported a potent neuropreservatory effect of IVIG against ROS-
mediated oxidative insults in primary human neurons [25]. Moreover, IVIG was also shown 
to prevent neurofibrillary degeneration of CA1 hippocampal neurons in vivo in the 3xTg 
mouse [21]. Plasma gene expression profiling experiments revealed that IVIG stabilizes 
cytoskeletal and calcium signaling plasticity and phosphorylation-based cellular homeostatic 
mechanisms in the face of mounting AD pathology in these mice. Here, we show that IVIG 
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also preserves cellular antioxidant defense mechanisms that may serve as the basis for its 
ability to prevent ROS-mediated neuronal cell death. Taken together, these data show that 
IVIG treatment has great potential to preserve and protect neurons by abrogating AD-related 
oxidative insults (Fig. 5) and presents a powerful preclinical tool for understanding these 
mechanisms.
Our results also suggest that IVIG treatment even at high doses (20 mg/ml) was well 
tolerated by human brain cultures, including primary neurons, as there was neither cellular 
toxicity nor a loss of cell viability as assessed by several independent techniques, including 
morphology, CTG and LDH assays. Furthermore, IVIG treatment did not affect any 
behavioral phenotypes or mortality in 3xTg mice (not shown). These observations mimic the 
good safety profile for IVIG in previous clinical trials and underscore its importance as a 
promising therapeutic agent for further clinical trials. If the dosage, duration, and other 
treatment conditions are adequately optimized, then IVIG treatment may fulfill its promise 
to prevent and delay the onset of AD pathology and symptoms
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Fig 1. IVIG preserves and promotes membrane integrity in human primary neurons
HFB were prepared and seeded (2–3×105 cells/well) onto 24-well plates as described 
previously [26]. At DIV16, cells were treated for four days with either media, vehicle 
(glycine buffer), negative control (Buminate, Baxter), IVIG (Gammagard 10%, Baxter) 10 
mg/mL or IVIG 20 mg/mL. At the end of the treatments, the conditioned medium (CM) 
samples were collected from each well without disturbing the cells. An equal volume of CM 
was subjected to the LDH assay as described previously. The data are shown as the 
percentage of total LDH in the CM from each treatment vs percent mean media control (set 
to 100). A significant decrease in LDH release with IVIG treatment vs the control media 
(ANOVA, p < 0.05) suggests the preservation and enhancement of the cell membrane 
integrity with IVIG treatments.
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Fig 2. IVIG preserves cell viability in human primary neurons
HFB cultures (DIV16) were prepared, cultured, seeded and treated as describe in Fig. 1. At 
the end of the treatments, the CTG-based cell viability assay was performed with an equal 
volume of cell suspension. The data are shown as the percentage of CTG from the percent 
mean control (100%). CTG assay shows a significant increase in cell viability with high 
dose of IVIG (20 mg/mL) treatment (ANOVA, p < 0.05). This range of IVIG treatments was 
well-tolerated by the neuronal cells. Cellular morphology was unaltered at the 
concentrations tested (not shown).
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Fig 3. IVIG treatments protect human neurons and against ROS insults
Human fetal brain cultures (DIV16) were prepared, cultured and seeded as described in Fig. 
1. For the ROS experiments, the cell culture contained ‘antioxidant-free B27’ media for each 
respective treatment. The HFB cells were first exposed with H2O2 on each well at 37C for 
24 hr. Following H2O2 insult, media were aspirated off from each well and the HFB cells 
were washed with PBS. The HFB cells were then treated with either medium, glycine, 
Buminate, IVIG 10 mg/ml or IVIg 20 mg/ml for 72 hr. At the end of the treatments, the 
CTG-based cell viability assay was performed with an equal volume of cell suspension. 
CTG assay shows a significant decrease in cell viability when the cells were prior insulted 
with ROS (vehicle +ROS). Brain cultures containing neurons were not rescued against ROS 
pre-exposure in the presence of either glycine or Buminate. Notably, neuron containing 
cultures were gradually rescued against ROS pre-exposure in the presence of increasing 
dose of IVIG. Thus, IVIG pre-treatment protects human neurons from ROS-mediated 
damage.
Counts et al. Page 10
J Clin Immunol. Author manuscript; available in PMC 2015 July 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig 4. IVIG regulates plasma and hippocampal levels of antioxidant mRNAs in 3xTg mice
A) IVIG increases plasma levels of select mRNAs regulating detoxifying antioxidant 
pathways. Bar graph shows that six months of placebo treatment resulted in a 40–60% 
reduction in the expression levels of transcripts encoding superoxide dismutase 2 (SOD2), 
catalase (CAT), glutathione S-transferase 1 (GST1), and glutathione peroxidase 1 (GPX1) 
compared to baseline, whereas six months of IVIG treatment preserved the levels of these 
antioxidant enzyme transcripts. n = 12/group *, p < 0.01 compared to baseline, **, p < 0.001 
compared to baseline, via one-way ANOVA with Bonferroni’s post hoc test for multiple 
comparisons. B) Antioxidant transcript levels are also preserved in the hippocampus of 
IVIG-treated mice. Bar graphs show relative expression levels of SOD2, GST1, and 
carbonyl reductase 1 (CBR1) in placebo and IVIG-treated mice compared to baseline, as 
quantified by qPCR. SOD2 and GST1 levels were reduced by ~40% in placebo-treated 
mice, whereas levels of these transcripts were unchanged in IVIG-treated mice. n = 6/group 
*, p < 0.05 compared to baseline, via one-way ANOVA with Bonferroni’s post hoc test for 
multiple comparisons. Other abbreviations: SOD1 (superoxide dismutase 1), GSR 
(glutathione reductase), GLRX (glutaredoxin).
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Figure 5. Schematic diagram highlighting the potential role of IVIG as an anti-oxidant, anti-
inflammatory and neuroprotective agent
Neurochemical dysfunctions associated with AD include the accumulation of inflammatory 
factors, glial activation, and reactive oxygen species (ROS). These factors are belived to 
contribute to pathological cascades leading to neurodegeneration and synaptic loss and AD. 
According to the amyloid hypothesis, AD results from the accumulation of potentially toxic 
Aβ peptides as extracellular senile plaques. Aβ is cleaved from the amyloid-β precursor 
protein (APP) sequentially by secretase enzymes. As discussed in the text, IVIG treatment 
has been shown to lower the hallmark AD pathology, including amyloid plaques, 
neurofibrillary tangles, inflammation, and oxidative stress using the neuronal cell culture 
and transgenic mouse models of AD. IVIG administration has produced significant effects 
on inflammation and synaptic function in the AD Tg mice model. At the tissue culture front, 
IVIG-treatment increased levels of synaptic proteins in primary rat hippocampal neurons. 
Furthermore, when the neuronal cells were challenged with oxidative stress agents, the IVIG 
treatment protected against neurotoxic insults. Therefore, IVIG treatment displays 
significant translational value for unveiling AD pathogenic mechanisms and potential 
preventive and therapeutic strategies for AD.
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